Curry Barker has secured a third horror feature with Universal Film Group and Blumhouse-Atomic Monster, cementing a productive partnership between the filmmaker and the two production companies. Barker will write, direct, and produce the untitled project, continuing a streak that began with his breakout hit The Obsession, which grossed $297 million globally and remains a commercial force at the box office.
The deal arrives as Barker's filmography expands within the Blumhouse and Atomic Monster ecosystem. Between The Obsession and this new project lies Anything But Ghosts, a supernatural thriller scheduled for release through the partnership. Blumhouse and Atomic Monster, the horror banner run by producer James Wan, have built their reputation on identifying emerging directorial talent and granting creative autonomy to filmmakers willing to deliver genre entertainment on disciplined budgets.
Barker's trajectory mirrors a pattern in contemporary horror distribution. Young directors arrive with debuts that capture audience appetite for spectacle and scares, then leverage those successes into broader deals that allow for both artistic ambition and commercial predictability. The Obsession proved audiences would follow Barker's vision into theaters, a validation that justifies the studio's confidence in his second and now third features.
Universal and Blumhouse have deepened their collaboration in recent years, with the former distributing the latter's theatrical releases while maintaining production oversight. This arrangement provides emerging filmmakers with both studio resources and the creative latitude that independent horror production traditionally offered. Barker's three-picture commitment signals that Universal and Blumhouse view him as a franchise-building talent capable of delivering consistent returns.
The continued success of The Obsession, even months after its theatrical debut, suggests audience appetite for Barker's sensibility remains robust. That durability at the box office justifies expansion of his deal and positions his upcoming projects as reliable commercial bets within horror's increasingly crowded theatrical landscape.